Key Points
- Insider sale: SOPHiA GENETICS insider Zhenyu Xu sold 4,000 shares on July 13 at an average price of $5.70, totaling $22,800. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Recent selling activity: Xu also sold 7,393 shares on July 6 and 608 shares on April 20, indicating a pattern of recent insider sales. After the latest transaction, Xu still held 610,887 shares valued at about $3.48 million.
- Company snapshot: SOPHiA GENETICS stock was down 0.7% and traded around $5.68, near its 50-day moving average of $5.19. The company recently reported a quarterly EPS loss that missed estimates, though revenue came in above expectations.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 4,000 shares of the stock in a transaction on Monday, July 13th. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00. Following the completion of the sale, the insider owned 610,887 shares of the company's stock, valued at approximately $3,482,055.90. This represents a 0.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zhenyu Xu also recently made the following trade(s):
- On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.
- On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total transaction of $3,167.68.
SOPHiA GENETICS Stock Down 0.7%
Shares of SOPH stock opened at $5.68 on Wednesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm's 50-day moving average is $5.19 and its 200-day moving average is $5.00. The stock has a market cap of $476.50 million, a price-to-earnings ratio of -10.92 and a beta of 0.96. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.
Analyst Ratings Changes
Several research firms have commented on SOPH. BTIG Research reiterated a "buy" rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS has an average rating of "Hold" and an average price target of $7.50.
Check Out Our Latest Analysis on SOPH
Institutional Trading of SOPHiA GENETICS
Hedge funds have recently added to or reduced their stakes in the company. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth $49,000. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS during the 1st quarter worth $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. 31.59% of the stock is owned by institutional investors and hedge funds.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
